Cutaneous T-cell Non-hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for Cutaneous T-cell Non-hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-08-13Clinical Trial Results: Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma [Phase 2]
Phase 2 trial evaluating Brentuximab Vedotin in combination with Lenalidomide for relapsed or refractory T-cell lymphoma including cutaneous…
-
CLINICAL_TRIALS trial_result · 2025-09-18Clinical Trial Update: Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial is evaluating durvalumab with or without lenalidomide in patients with relapsed or refractory cutaneous or periph…
-
CLINICAL_TRIALS trial_result · 2025-01-17Clinical Trial Update: Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas [Phase 1]
Phase 1 trial update evaluating the combination of romidepsin and parsaclisib for relapsed or refractory T-cell lymphomas; the study status …
-
CLINICAL_TRIALS trial_result · 2024-08-13Clinical Trial Update: Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides [Phase 1, Phase 2]
Phase 1/2 study of mogamulizumab in combination with extracorporeal photopheresis for Sezary syndrome and mycosis fungoides was terminated.
-
CLINICAL_TRIALS trial_result · 2024-04-10Clinical Trial Update: Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma [Phase 2]
Phase 2 trial evaluating the combination of romidepsin and lenalidomide in previously untreated peripheral T-cell lymphoma.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2018-12-14Clinical Trial Update: RFT5-dgA Immunotoxin in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma [Phase 2]
Phase 2 trial of RFT5-dgA immunotoxin for relapsed or refractory cutaneous T-cell lymphoma (a form of non-Hodgkin lymphoma) has been termina…